-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
UroGen Pharma Ltd. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2020 to Q2 2024.
- UroGen Pharma Ltd. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $38K, a 29.6% decline year-over-year.
- UroGen Pharma Ltd. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $3.94M, a 167% increase year-over-year.
- UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2023 was $3.92M, a 123% increase from 2022.
- UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2022 was $1.76M, a 21.1% increase from 2021.
- UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2021 was $1.45M, a 57.1% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)